Differences

This shows you the differences between two versions of the page.

--- home:diseases:eyes [01.26.2019] – [Recent research into AMD] sallieq
+++ home:diseases:eyes [02.11.2019] – [Initial response to olmesartan] sallieq
@@ Line 19: / Line 19: @@
 ===== Marshall Protocol for chronic eye diseases =====
 ==== Initial response to olmesartan ====
-It should be noted that some patients experience a drop in eye inflammation as soon as they start the ARB medication olmesartan.  This is because aside from its ability to stimulate the innate immune system, olmesartan has significant anti-inflammatory properties. Benicar binds and blocks the Angiotensin Receptor, decreasing levels of Nuclear Factor Kappa B, a protein that stimulates the release of inflammatory cytokines - causing a drop in inflammation.  For example, when researchers at the Keio University School of Medicine used a bacterial endotoxin to create a condition similar to uveitis in mice, they found that the eye inflammation of the animals decreased significantly after they were administered the ARB Telmisartan.(({{pubmed>long:16043867}}))
+It should be noted that some patients experience a drop in eye inflammation as soon as they start the ARB medication olmesartan.  This is because aside from its ability to stimulate the innate immune system, olmesartan has significant anti-inflammatory properties. Benicar binds and blocks the Angiotensin Receptor, decreasing levels of Nuclear Factor Kappa B, a protein that stimulates the release of inflammatory cytokines - causing a drop in inflammation.  For example, when researchers at the Keio University School of Medicine used a bacterial endotoxin to create a condition similar to uveitis in mice, they found that the eye inflammation of the animals decreased significantly after they were administered [[home:othertreatments:immune_suppressants:telmisartan|Telmisartan]],
+ a dangerously different ARB.(({{pubmed>long:16043867}}))
@@ Line 87: / Line 88: @@
 We would caution intake of supplementary antioxidants for those with ocular disease.   (({{pubmed>long:28582804}}))
+==== Diabetic macular edema ====
+An increase in the serum levels of homocysteine was present within patients with type 2 diabetes compared to healthy individuals. The mean total plasma homocysteine levels were associated with a greater central subfield macular thickness (CSMT), average macular thickness (AMT), and average macular volume (AMV) in patients with type 2 diabetes without DME, after adjusting for age, sex, duration of diabetes, and HbA1c.
+CONCLUSIONS:
+Higher homocysteine levels were associated with an increased CSMT, AMT, and AMV in diabetic patients without DME. This link may indicate that patients with type 2 diabetes with increased levels of plasma tHcy are more prone to develop a clinical manifestation of DME.   (({{pubmed>long:28391536}}))
 ==== Cataracts ====

home/diseases/eyes.txt · Last modified: 09.14.2022 by 127.0.0.1